Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study will examine a new combination of drugs: Capecitabine and Oxaliplatin for the
treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by
the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs
is experimental (not approved by the FDA as standard treatment), but is a widely used
treatment option and preliminary studies have shown that treatment with the combination has a
positive effect on metastatic colorectal cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
State Key Laboratory of Cancer Biology
Collaborators:
Beihua University Chengdu Medical College Shanghai Jiao Tong University School of Medicine Tianjin Union Medical Center